Pathogenic autoreactive effector T cells and other immune effector cells (Teff)

Pathogenic autoreactive effector T cells and other immune effector cells are the primary cellular drivers of tissue damage in autoimmune diseases, where the immune system mistakenly attacks host antigens. These cells, primarily activated CD4+ and CD8+ T lymphocytes, orchestrate chronic inflammation by secreting pro-inflammatory cytokines like interferon-gamma and interleukin-17 and by directly killing target cells. In conditions such as Type 1 Diabetes, Multiple Sclerosis, and Rheumatoid Arthritis, the therapeutic goal is to selectively modulate or eliminate these pathogenic populations while preserving general immunity. Current pharmacological strategies include monoclonal antibodies that target surface markers like CD3 or CD6, costimulation blockers, and broad immunosuppressants. Emerging cellular therapies, such as CAR-T cells and engineered regulatory T cells, offer the potential for more precise targeting of these autoreactive clones. However, the systemic suppression of these effector cells carries significant risks, most notably an increased susceptibility to infections and potential for severe inflammatory reactions like cytokine release syndrome. Monitoring these cells via surface markers and cytokine profiles is essential for assessing treatment efficacy and patient safety.

Other names

Autoreactive T cellsPathogenic T cellsEffector T cellsSelf-reactive lymphocytesPro-inflammatory immune cellsTeff cells

Therapeutic agents target these cells through various mechanisms, including direct depletion via antibody-dependent cellular cytotoxicity (ADCC), inhibition of T-cell receptor (TCR) signaling, blockade of co-stimulatory molecules (e.g., CD28/B7), and the induction of immune tolerance or anergy.